Creative Medical Technology Holdings Inc. (CELZ)
NASDAQ: CELZHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CELZ stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.53M
- EPS (TTM)
- -$2.07
- Dividend yield
- None
- 52-week range
- 0.62 – 6.25
- Day range
- 0.8601 – 0.893
- Volume / Avg
- 39.26K / 6.77M
- Beta
- —
- Shares outstanding
- 7.59M
- Next earnings
- Nov 6, 2026
52-week range
CELZ stock today
On Oct 8, CELZ ended the session at $0.8604, shedding $0.0216 (2.45%), versus the S&P 500's 0.47% decline. Trading was light, with 39.26K shares changing hands, about 1% of the average daily volume. At this level, CELZ sits near the bottom of its 52-week range of $0.62 to $6.25: 86.2% below the high and 38.8% above the low.
Creative Medical Technology has posted a net loss over the last twelve months (EPS of -$2.07), so its P/E ratio is not meaningful. Creative Medical Technology's next earnings report is expected on Nov 6, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Creative Medical Technology
Company profileCreative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Timothy Warbington
- Headquarters
- Phoenix, AZ
- Employees
- 4
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$20.00+2224.50%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 6, 2026
- EPS estimate
- $-0.24
Creative Medical Technology peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XCURExicure Inc. | 1.00 | -1.96% | $6.55M | vs CELZ |
| ALZNAlzamend Neuro Inc. | 1.34 | -2.19% | $6.47M | vs CELZ |
| LEXXLexaria Bioscience Corp. | 3.20 | -8.57% | $6.74M | vs CELZ |
| EVGNEvogene Ltd | 0.3985 | -2.95% | $6.30M | vs CELZ |
| NRSNNeuroSense Therapeutics Ltd. | 3.58 | -6.28% | $6.79M | vs CELZ |
| ENVBEnveric Biosciences Inc. | 1.52 | +1.67% | $6.80M | vs CELZ |
| ACXPAcurx Pharmaceuticals Inc. | 1.25 | -3.85% | $6.95M | vs CELZ |
| CANFCan-Fite Biopharma Ltd ADR | 2.00 | -4.76% | $6.06M | vs CELZ |
Indexes, lists and sector
Appears in lists
Creative Medical Technology stock FAQ
What is Creative Medical Technology's stock price today?
CELZ last traded at $0.8604 as of Oct 8, 4:00 PM EDT, down 2.45% on the day. Prices are delayed at least 15 minutes.
When is Creative Medical Technology's next earnings date?
Creative Medical Technology is expected to report earnings on Friday, November 6, 2026. Analysts expect EPS of $-0.24.
Who is Creative Medical Technology's CEO?
Mr. Timothy Warbington is the chief executive officer of Creative Medical Technology Holdings Inc., which has about 4 employees.
What is the CELZ 52-week high?
The 52-week high for CELZ is $6.25 and the 52-week low is $0.62. The stock is currently 86.2% below its high.